CJClaire Julian-Reynier

Claire Julian-Reynier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claire Julian-Reynier has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review

    by B. Meiser, W. K. T. Wong, M. Peate, C. Julian-Reynier, J. Kirk, G. Mitchell

    Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use ‘s amongst high-risk women. Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women’s decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed primary clinical studies. A range of factors were identified as motivators of, and barriers to, tamoxifen uptake including: perceived risk, breast-cancer-related anxiety, health professional recommendation, perceived drug effectiveness, concerns about side-effects, knowledge and access to information about side-effects, beliefs about the role of risk-reducing medication, provision of a biomarker, preference for other forms of breast cancer risk reduction, previous treatment experience, concerns about randomization in clinical trial protocols and finally altruism. Results indicate that the decision for high-risk women regarding tamoxifen use or non-use as a risk-reducing medication is not straightforward. Support of women making this decision is essential and needs to encompass the full range of factors, both informational and psychological.


  • Les représentations de la maladie : choix des outils de mesure et applications dans le champ du cancer

    by L. Restivo, T. Apostolidis, C. Julian-Reynier

    Résumé Objectif Dresser un bilan des outils quantitatifs disponibles pour mesurer les représentations de la maladie et analyser leur utilisation empirique auprès de patients atteints de cancer. Matériel et méthodes Revue de la littérature. Résultats Sept outils de mesure des représentations de la maladie existent dont un spécifique au cancer. L’Illness Perception Questionnaire est utilisé dans 29 des 33 études retenues. Conclusion Associer ces échelles avec des méthodes reposant sur des approches davantage centrées sur le contexte socioculturel semble à privilégier.


  • “Maybe they have found something new” participants’ views on returning cohort psychosocial survey results

    by Eve Bureau, Isabelle Pellegrini, Catherine Noguès, Christine Lasset, Claire Julian‐Reynier

    Although greater attention is currently being paid to participants in research, no studies have dealt so far with the issue of returning aggregate psychosocial results to cohort participants. (i) To explore participants' views about disclosure of the aggregate results of a French national psychosocial cohort survey on the epidemiology of preventive behaviour in women from families with a hereditary breast cancer risk. (ii) To assess whether it is worth consulting participants before designing the disclosure process. A qualitative study using semi-structured face-to-face interviews and a thematic analysis based on Grounded Theory methods. Nineteen interviews were conducted with cancer-free female BRCA mutation carriers/non-carriers aged 31-79 who had participated in a cohort survey by answering self-administered questionnaires. Participants showed considerable interest in the issue of result disclosure. The preferences expressed about disclosure were rarely relevant to the topic investigated, however, as they often focused on medical knowledge about BRCA and not on the psychosocial findings obtained. This confusion may have been due to the participants' experience of the survey procedures, including its longitudinal nature, the occurrence of very few interactions with the investigators and the wide range of topics addressed in the questionnaires. Investigators should ascertain participants' expectations and preferences by consulting them before disclosing the results obtained. Although the disclosure process may not meet participants' expectations completely, consultation is the key to preventing them from having irrealistic expectations about the information they are going to receive.


  • Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?

    by Christine Maheu, Anne‐Deborah Bouhnik, Catherine Nogues, Emmanuelle Mouret‐Fourme, Dominique Stoppa‐Lyonnet, Christine Lasset, Pascaline Berthet, Jean‐Pierre Fricker, Olivier Caron, Elizabeth Luporsi, et al.

    Objective The aim of this study is to prospectively determine the factors contributing to whether unaffected women from BRCA1/2 families reported that clinicians proposed psychological consultations and that they had attended these consultations during the genetic testing process. Methods A prospective study was performed on a national cohort, using self‐administered questionnaires to determine the rates of proposal and use of psychological services at the time of BRCA1/2 test result disclosure (N = 533) and during the first year after disclosure (N = 478) among unaffected French women from BRCA1/2 families who had undergone genetic testing for BRCA1/2. Multivariate adjustment was carried out using logistic regression models fitted using generalized estimation equations, with the genetic testing centre as the clustering variable. Results At the time of BRCA1/2 test result disclosure, a psychological consultation was proposed by cancer geneticists to 72% and 32% of the carriers (N = 232) and noncarriers (N = 301), respectively (p < 0.001). One year after disclosure, 21% of the carriers had consulted a psychologist, versus 9% of the noncarriers (p < 0.001). Both the proposal and the uptake depended on the women's BRCA1/2 mutation carrier status (proposal adjusted odds ratio (AOR): 4.9; 95% confidence interval (CI) 3.4–7.2; uptake AOR: 2.2; 95% CI 1.2–4.0), their level of education (proposal AOR: 1.7; 95% CI 1.1–2.7; uptake AOR: 4.5; 95% CI 1.7–12.1) and the distress they experienced about their genetic test results (proposal AOR: 1.02; 95% CI 1.01–1.03; uptake AOR: 1.04; 95% CI 1.02–1.06) Conclusions Determinants of the proposal/uptake of psychological consultations in the BRCA1/2 testing process highlight the need for inventive strategies to reach the different types of women's profiles. Copyright © 2013 John Wiley & Sons, Ltd.


  • Open Access

    Psychometric properties of a French version of a Dutch scale for assessing breast and body image (BBIS) in healthy women

    by Noémie Resseguier, Catherine Noguès, Roch Giorgi, Claire Julian-Reynier

    Background: Genetic testing among women for BRCA1/2 mutation can have various psychological effects, such as those focusing on body image. The aim of this study was to examine the psychometric properties of a generic scale assessing breast and body image (BBIS) in healthy women tested for BRCA1/2 mutations. Methods: A Dutch body image scale focusing on both general and breast-related body image was translated into French. It was presented to a French cohort of female cancer-free BRCA1/2 mutation carriers and non-carriers (N = 568). The psychometric properties of the scale were studied by assessing its dimensional and factorial structure, internal consistency, construct-related validity, and external validity. Results: The scale was found to be a satisfactory psychometric tool for assessing both body image and breast image. The three main dimensions which emerged were classified under the headings “values attached to body image”, “satisfaction with body image and perceived attractiveness”, and “satisfaction with breasts”. The BBIS scores were not significantly associated with the participants’ socio-demographic characteristics or their BRCA1/2 mutation carrier status, but significant associations were observed between these scores and the women’s medical and behavioural characteristics. Conclusions: The BBIS is a generic tool which can be used to assess body image in either affected or unaffected women. The scale will have to be administered to other populations in order to confirm its validity.


  • Is the psychological impact of genetic testing moderated by support and sharing of test results to family and friends?

    by Genepso Cohort, Julie Lapointe, Michel Dorval, Catherine Noguès, Roxane Fabre, Claire Julian-Reynier

    Receiving the results of genetic tests for a breast and ovarian cancer susceptibility can be a stressful experience. Here we studied the effects of social support (SS) and the sharing of test results on the psychological impact of BRCA1/2 test result disclosure. We also compared carriers and non-carriers on sharing, SS and psychological impact. Five-hundred and twenty-two unaffected women were followed prospectively for 2 years after receiving their test results. Psychological impact was measured on the impact of event scale. Multivariate multi-level models were used, and all the analyses were stratified depending on mutation status (carriers vs non-carriers). Two weeks after receiving their BRCA1/2 results, carriers had shared their test results less frequently than non-carriers (p < 0.01). Sharing test results was not significantly associated with psychological impact. Availability of SS was significantly associated with better psychological adjustment across time among carriers (p < 0.01), but not among non-carriers. For female BRCA1/2 mutation carriers, the importance of SS should be stressed, and possible ways of enlisting people in their entourage for this purpose should be discussed in the context of clinical encounters.


  • Open Access

    BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis

    by Claire Julian-Reynier, Roxane Fabre, Isabelle Coupier, Dominique Stoppa-Lyonnet, Christine Lasset, Olivier Caron, Emmanuelle Mouret-Fourme, Pascaline Berthet, Laurence Faivre, Marc Frenay, et al.


  • Open Access

    La recherche biomédicale à l’ère des tumorothèques

    by Julien Mancini, Christian Chabannon, Norbert Vey, Lise-Marie Billard-Daufresne, Isabelle Pellegrini, Claire Julian-Reynier

    In French hospitals, patients are increasingly asked to participate in research, particularly in oncology where the development of research is stimulated at a national level (plan Cancer). This article express our thoughts based on the literature about the perception by cancer patients of research activities developed in the care centre where they are treated. We focus mainly on the consent for biobanking in a context in which cancer patients are routinely requested to donate tumour samples for research. This article presents the results of a survey among patients treated in a comprehensive cancer centre. The available literature shows that patients have an overall positive image of medical research and of the existence of research activities intertwined with medical care. Patients are globally expressing a wish for more proposals to participate in research in collaboration with scientific teams.


  • Open Access

    Chimiothérapie ciblée du cancer du sein basée sur une analyse génomique de la tumeur

    by Isabelle Pellegrini, Myrto Rapti, Jean-Marc Extra, Anouk Petri-Cal, Themis Apostolidis, Jean-Marc Ferrero, Thomas Bachelot, Patrice Viens, François Bertucci, Claire Julian-Reynier

    The purpose of this review of the literature is to document how breast cancer patients perceive the use of tumor gene profiling approaches to better adapt treatments, and to identify the features of these approaches that may impact their clinical application. In general, the use of tumor genomic analysis was perceived by patients as an approach facilitating personalized medicine and received considerable support. Nevertheless, a number of confusions and worries about these practices were also identified. Improving the quality of provider/patient communications should enable patients to play a more active part in the decision-making about their treatment. This will ensure that those who agree to their tumor gene analysis have realistic expectations and sound deductions of the final result disclosure process.